---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000230"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:13:14.646945+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Aldeyra Therapeutics presents at Oppenheimer Healthcare Conference; no material new financial data disclosed

## Summary
- CEO Todd Brady participates virtually in fireside chat at Oppenheimer 34th Annual Healthcare Life Sciences Conference on Feb 13, 2024.
- Discussion covers clinical and regulatory status of Aldeyra's product candidates for immune-mediated diseases.
- Corporate presentation furnished as Exhibit 99.1; no earnings or financial guidance provided.
- Filing is Regulation FD disclosure; presentation not incorporated by reference.
- No specific milestones, data readouts, or financial results announced in the exhibit.

## SEC filing metadata
- accession: 0001157523-24-000230
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752324000230/0001157523-24-000230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752324000230/a53895165.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000230
- JSON: https://secwatch.observer/filing/0001157523-24-000230.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.